Esperion Therapeutics will be acquired by ARCHIMED in a deal valued at up to $1.1 billion, with shareholders receiving $3.16 per share in cash plus the right to up to $100 million in contingent milestone payments based on future sales. The upfront cash price represents a 58% premium over Esperion's closing price on April 30, 2026. The acquisition aims to support Esperion’s growth in cardiometabolic therapies, with the transaction expected to close in Q3 2026 after shareholder and regulatory approvals. Post-acquisition, Esperion will become a private company and delist from Nasdaq.
Moneco Advisors has integrated three new advisory teams, adding approximately $250 million in assets and four advisors to its platform. This brings the firm's total assets under management to over $3 billion across seven offices in New England and th...
NMI Holdings, Inc. announced that its President and CEO, Adam Pollitzer, will participate in Moody’s US Housing Executive Series broadcast on May 28, 2026. This event highlights NMI’s role in the mortgage insurance market, supporting low-down-payment...
Inventiva, a biopharmaceutical company developing a treatment for metabolic dysfunction-associated steatohepatitis (MASH), reported €75 million in cash and equivalents and €121.5 million in short-term deposits as of March 31, 2026. The company record...
QNB Corp., the parent company of QNB Bank, announced a quarterly cash dividend of $0.39 per share. The dividend will be paid on June 26, 2026, to shareholders recorded as of June 12, 2026. This dividend reflects the company's ongoing commitment to re...
UP Fintech Holding Limited is under investigation for possible securities fraud following a crackdown by Chinese regulators on brokers operating without licenses. The China Securities Regulatory Commission and other agencies targeted UP Fintech's par...
